263 related articles for article (PubMed ID: 9428456)
21. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
22. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
Suh H; Wadhwa NK
Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
[TBL] [Abstract][Full Text] [Related]
23. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
Park L; Uhthoff T; Tierney M; Nadler S
Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
[TBL] [Abstract][Full Text] [Related]
24. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
25. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
Ahsan N
Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
[TBL] [Abstract][Full Text] [Related]
26. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
Besarab A; Dalton CL
Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
28. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients.
Greenbaum LA; Pan CG; Caley C; Nelson T; Sheth KJ
Pediatr Nephrol; 2000 Sep; 14(10-11):908-11. PubMed ID: 10975297
[TBL] [Abstract][Full Text] [Related]
29. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
DeVita MV; Frumkin D; Mittal S; Kamran A; Fishbane S; Michelis MF
Clin Nephrol; 2003 Nov; 60(5):335-40. PubMed ID: 14640239
[TBL] [Abstract][Full Text] [Related]
30. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
[TBL] [Abstract][Full Text] [Related]
31. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
32. A trial of two iron-dextran infusion regimens in chronic hemodialysis patients.
Agarwal R; Davis JL; Hamburger RJ
Clin Nephrol; 2000 Aug; 54(2):105-11. PubMed ID: 10968685
[TBL] [Abstract][Full Text] [Related]
33. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
34. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
Ahsan N
Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
[TBL] [Abstract][Full Text] [Related]
35. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients.
Anuradha S; Singh NP; Agarwal SK
Ren Fail; 2002 May; 24(3):307-13. PubMed ID: 12166697
[TBL] [Abstract][Full Text] [Related]
36. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Malovrh M; Hojs N; Premru V
Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies.
Sloand JA; Shelly MA; Erenstone AL; Schiff MJ; Talley TE; Dhakal MP
Perit Dial Int; 1998; 18(5):522-7. PubMed ID: 9848632
[TBL] [Abstract][Full Text] [Related]
38. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
[TBL] [Abstract][Full Text] [Related]
39. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
Hood SA; O'Brien M; Higgins R
Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
[TBL] [Abstract][Full Text] [Related]
40. [Iron supplementation during erythropoietin therapy in patients on hemodialysis].
Svára F; Sulková S; Kvasnićka J; Polakovic V
Vnitr Lek; 1996 Dec; 42(12):849-52. PubMed ID: 9072885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
